Read our COVID-19 research and news.

Webinar Technology

Accelerating antibody characterization through flow cytometry

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Accelerating antibody characterization through flow cytometry

09 June 2021

12:00 p.m. ET

Register to watch recording


The application of monoclonal antibodies (mAbs) and antibody drug conjugates as biologic drug therapies is an area of highly active research. Antibody characterization is an essential part of the biopharmaceutical development process. It is needed to differentiate among biologics/biosimilars, to help screen mAb drug candidates, to optimize production processes, and to satisfy regulatory requirements. Initially, the generation of monoclonal antibodies involved fusing cells from tissues and tumors to create hybridomas—a costly and often low-yield undertaking. Today, cell-line development and more efficient manufacturing techniques have emerged. Furthermore, a range of methods are used to determine the class and subclass of the antibody, including ELISA, radioimmunoassay, surface plasmon resonance, Western and dot blotting, mass spectrometry, and flow cytometry. In this webinar, the speakers will discuss how flow cytometry has advanced antibody characterization and how this method is used in their respective fields of research.

During the webinar, the speakers will:

  • Discuss the importance of therapeutic antibodies, the challenges of their isolation, and the future of the field
  • Offer general background on the importance of, and methods for, antibody characterization, with an emphasis on flow cytometry
  • Outline the differences of traditional flow vs. advanced flow cytometry for antibody characterization
  • Provide an overview of the spectrum of antibody characterization tools and highlight the benefits of advanced flow cytometry
  • Answer your questions live during the broadcast.

This webinar will last for approximately 60 minutes.

Speaker bios

Katja Hanack, Ph.D.

University of Potsdam
Potsdam, Germany

Dr. Hanack received her Ph.D. in biomaterial sciences in 2006 from the University of Potsdam, Germany, where she has been the Endowed Chair of Immunotechnology since 2015. Her laboratory works on improving technologies for antibody production, including the creation of monoclonal antibodies through hybridomas via the use of transgenic fusion cell lines, use of virus-like particles to create an antibody response, and generation of camelid monoclonal antibodies and nanobodies. She is also founder of the custom monoclonal antibody company new/era/mabs GmbH.

Will Howat, Ph.D

Cambridge, UK

Dr. Howat is Abcam’s senior director of validation and technical quality. Prior to joining Abcam in 2018, he worked at AstraZeneca as team leader of its molecular pathology group, where his team developed biomarker assays for preclinical, phase 1, and phase 2 clinical trials. Before that he was at Cancer Research UK’s Cambridge Institute, where he set up and ran the Histopathology/ISH core facility for 9 years. He has also worked at the Wellcome Sanger Institute on the Atlas of Protein Expression and was responsible for R&D within the immunohistochemistry group. Dr. Howat received his Ph.D. in pathology from the University of Southampton. His publications span key journals such as The Lancet, Nature, Science, Nature Genetics, The American Journal of Pathology, and The Journal of Pathology.

Nina Senutovitch, Ph.D.

Albuquerque, NM

Dr. Senutovitch received her B.Sc. in biochemistry from New Mexico State University. She completed her Ph.D. in biological sciences at Carnegie Mellon University, where she developed and detailed the function of novel fluorescent probes. As a postdoctoral fellow at the University of Pittsburgh, she established biosensor-based live-cell screening assays for the detection of hepatotoxicity, including the use of a human liver “organ-on-a-chip” model. She joined Sartorius in 2019 as a senior scientist in Cell Analytics. 

Jackie Oberst, Ph.D.

Washington, DC

Dr. Oberst did her undergraduate training at the University of Maryland, College Park, and her Ph.D. in Tumor Biology at Georgetown University, Washington D.C. She combined her interests in science and writing by pursuing an M.A. in Journalism from the Philip Merrill College of Journalism at the University of Maryland, College Park. Dr. Oberst joined Science/AAAS in 2016 as the Assistant Editor for Custom Publishing. Before then she worked at Nature magazine, the Howard Hughes Medical Institute, The Endocrine Society, and the National Institutes of Mental Health.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here